Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 7, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 9,948 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 6, 2006, and was advised to the Company on September 7, 2006.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—are interested in the shares held in the GSK Trust in the same capacity as other employees. No guidance, outlook, or specific risk factors regarding business operations are provided in this text.
Key Facts for Investor Verification
- Transaction Date: September 6, 2006.
- Shares Transferred: 9,948 Ordinary Shares.
- Source: GlaxoSmithKline Employee Trust (Abacus (GSK) Trustees Limited).
- Beneficiaries: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Directors Involved: Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop (as interested parties in the trust).